How to Value an ENT Practice in 2026

ENT practices have become one of the most actively acquired physician specialties in the country. Private equity discovered otolaryngology about five years ago, and the consolidation wave has fundamentally reshaped what these practices are worth. Platform transactions by groups like US ENT Partners, ENT Specialty Partners, and several PE-backed roll-ups have established a market for ENT practices that didn't exist a decade ago.

If you're an otolaryngologist thinking about selling your practice, the first thing you need to understand is that your practice is probably worth more than you think — but only if it's structured in a way that buyers actually want. Let me explain what drives ENT practice value in 2026.

The Typical Valuation Range

ENT practices currently trade in a wide range: 4-8x EBITDA, with the spread driven primarily by whether you're selling to another physician or to a PE-backed platform. Solo practitioners without ancillary revenue streams tend to cluster at 4-5x. Multi-physician groups with integrated audiology, allergy, and in-office procedure suites are consistently commanding 6-8x from institutional buyers.

The EBITDA methodology is standard for ENT because most buyers are either PE platforms or hospital systems, both of which think in EBITDA terms. Solo practices under $1.5M in revenue selling to another physician may use SDE, but those transactions are increasingly rare as the PE platforms dominate the buyer landscape.

Why PE Loves ENT

Private equity has poured into otolaryngology for specific structural reasons that you should understand because they directly affect your valuation.

Ancillary revenue density. Unlike many physician specialties where the only revenue comes from office visits and hospital-based surgery, ENT practices can house multiple revenue streams under one roof: audiology and hearing aid sales, allergy testing and immunotherapy, in-office sinus procedures (balloon sinuplasty), sleep medicine, and facial plastics. Each ancillary line adds margin, and PE buyers are expert at optimizing these revenue streams post-acquisition.

Favorable reimbursement trends. In-office ENT procedures have been gaining ground with payers because they're dramatically cheaper than the same procedures performed in an ambulatory surgery center or hospital. Balloon sinuplasty in-office costs $3,000-$5,000 versus $15,000-$20,000 in a hospital setting. Payers are actively incentivizing the shift, which means in-office procedure revenue is growing, not shrinking.

Fragmented market. There are roughly 10,000 otolaryngologists in the US, and the vast majority practice in groups of 1-5 physicians. This fragmentation is exactly what PE roll-up strategies target: lots of small, independently run practices that can be acquired and professionalized under a single platform.

In-Office Procedures: The Value Multiplier

The single biggest driver of ENT practice value in 2026 is your in-office procedure capability. Practices that have invested in in-office sinus surgery (balloon sinuplasty, Propel stents), in-office eustachian tube dilation, and in-office laryngeal procedures are generating $300,000-$800,000+ in incremental revenue per physician from these services alone.

The margins on in-office procedures are extraordinary — typically 60-75% after supply costs and staff — because you're avoiding facility fees and capturing the full technical and professional component. A practice generating $500K in in-office procedure revenue at 65% margin is adding $325K of EBITDA. At a 7x multiple, that's $2.3M in incremental enterprise value from a single revenue line.

If you're not currently performing in-office procedures and you're 2-3 years from a potential sale, investing in the equipment and training now is one of the highest-ROI moves you can make. The capital outlay for a balloon sinuplasty setup is $50,000-$100,000. The return in practice value can be 10-20x that investment.

Audiology Integration and Hearing Aid Revenue

Audiology is the ancillary that most ENT practices already have in some form, but many are underperforming. A well-run audiology department in an ENT practice generates $400,000-$1,200,000 in revenue depending on patient volume and hearing aid sales volume.

The economics have changed over the past two years with the introduction of OTC hearing aids. The conventional hearing aid market ($4,000-$7,000 per pair) has compressed somewhat, but the reality is that OTC devices serve a different patient population than prescription hearing aids fitted by an audiologist. Patients with moderate-to-severe hearing loss still need professional audiological care, and those patients generate the highest margins.

What buyers look for in your audiology department: a dedicated audiologist (not just a hearing instrument specialist), a modern sound booth, relationships with premium hearing aid manufacturers (Phonak, Oticon, Starkey), and a patient recall system that drives annual follow-ups and upgrades. An audiology department that runs on referrals from your ENT physicians and has its own direct-access patient base is ideal.

Allergy Testing and Immunotherapy: Recurring Revenue Gold

Allergy services within an ENT practice are one of the most underappreciated value drivers. Here's why: allergy immunotherapy (allergy shots) generates weekly or biweekly recurring revenue for 3-5 years per patient. A patient on allergy shots visits your office 40-50 times per year, each visit generating $25-$50 in reimbursement plus the revenue from serum preparation.

An ENT practice with 200 active immunotherapy patients is generating roughly $250,000-$400,000 annually in highly predictable, recurring revenue. Buyers love this because it's the closest thing to a subscription model in physician services. The revenue doesn't depend on new patient acquisition — these patients are already committed to a multi-year treatment protocol.

Sublingual immunotherapy (allergy drops) is gaining traction as well and offers even better economics in some markets — patients pick up their drops monthly rather than coming in for injections, reducing staff time per visit while maintaining the recurring revenue stream.

What Drives ENT Practice Value Up

Multiple physicians. A group of 3-5 otolaryngologists is exponentially more attractive to PE than a solo practice. Multi-physician groups reduce key-person risk, enable call coverage without burnout, and provide the scale to support ancillary services that don't pencil out for a solo practitioner.

Diversified procedure mix. A practice performing sinus surgery, tonsillectomy/adenoidectomy, thyroid/parathyroid surgery, otologic procedures, AND in-office procedures is more resilient than one concentrated in a single procedure category. Reimbursement changes to any single CPT code won't devastate the practice.

ASC ownership or partnership. If you own a stake in an ambulatory surgery center where you perform procedures, that distribution income is extremely valuable. ASC distributions add directly to EBITDA and are highly regarded by PE buyers. Some of the highest ENT valuations I've seen include meaningful ASC income.

Clean payer mix. Commercial insurance and Medicare are the preferred payers. Heavy Medicaid exposure suppresses margins and multiple. Practices in markets with favorable commercial payer landscapes (employer-insured populations, limited managed Medicaid penetration) command premiums.

What Kills ENT Practice Value

Hospital employment contracts. If your physicians are employed by a hospital system under a professional services agreement, the practice itself may have limited standalone value. PE buyers need the physicians to be independent or willing to transition out of hospital employment, which can be contractually complex.

Aging physician without succession. A 62-year-old solo ENT with no associate and no transition plan is a declining asset. Buyers know the patient base will erode quickly after the selling physician reduces hours or retires. If you're within 5 years of retirement, recruit a younger partner now.

No ancillary revenue. An ENT practice that only does office visits and hospital-based surgery is leaving enormous value on the table. Buyers see this as upside they need to build, which means they're paying you a lower multiple today and capturing the ancillary revenue growth for themselves.

Deferred technology investment. Practices still using paper charts, without in-office CT capability (cone beam CT is standard for sinus evaluation), or with outdated audiometric equipment signal to buyers that significant capital investment is needed post-acquisition.

Preparing for Sale: The Strategic Playbook

Build your in-office procedure volume. If you're not already performing balloon sinuplasty and other in-office procedures, get trained and equipped. The incremental EBITDA from these procedures can add millions to your exit value.

Optimize your audiology department. Hire a strong audiologist if you don't have one. Build a hearing aid fitting and follow-up program that generates its own patient flow independent of ENT referrals.

Grow your allergy program. Every ENT practice should have an active allergy testing and immunotherapy program. The recurring revenue it generates is disproportionately valued by buyers.

Recruit a younger physician. Adding a physician 2-3 years before sale reduces owner dependency, increases revenue, and demonstrates to buyers that the practice can attract talent. A mid-career ENT joining your practice is one of the strongest signals you can send to the market.

Engage a healthcare M&A advisor. ENT practice sales to PE platforms are sophisticated transactions involving employment agreements, earnouts, equity rollovers, and complex tax structures. A generalist business broker is not equipped to navigate these deals. Work with an advisor who has closed physician practice transactions with PE buyers.

The Bottom Line

ENT practice valuation in 2026 is driven by ancillary revenue density more than any other single factor. A practice with robust in-office procedures, integrated audiology, and an active allergy immunotherapy program will command multiples that a clinic-only practice simply cannot achieve. The PE buyers are there, the capital is abundant, and the consolidation wave has years to run. Your job is to build the practice that buyers want to acquire — one with multiple revenue streams, multiple physicians, and operational infrastructure that scales. Do that, and the market will find you.